Advancing Vision Care With Formulation And Manufacture Of Ocular Therapeutics

According to Precedence Research, the global ophthalmic drug market is poised for significant growth, with its size expected to nearly double over the next decade — rising from $34.6 billion in 2021 to an estimated $68.93 billion by 2030. This growth is being driven by rapid advancements in the development of pharmacological interventions for various eye conditions, supported by innovative delivery systems and novel formulation strategies. For many of these conditions, especially those requiring surgery or corrective devices, eye drops play a critical role in both diagnosis and as part of pre- and post-surgery treatment regimens.

As the demand for ocular therapies increases, so too does the complexity of developing effective formulations. In this article, we explore the unique challenges faced in the formulation development of ocular therapies and how they can be overcome to ensure safe, efficient, and targeted treatments for patients.